Stoke Therapeutics (STOK) Long-Term Deferred Tax (2018 - 2021)

Stoke Therapeutics' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $66.0 million for Q4 2021.

• On a quarterly basis, Long-Term Deferred Tax rose 77.42% year-over-year to $66.0 million in Q4 2021; TTM through Dec 2021 was $66.0 million, a 77.42% increase from a year earlier, with the FY2021 full-year figure at $66.0 million, up 77.42% from the prior year.
• Long-Term Deferred Tax rose to $66.0 million in Q4 2021 per STOK's latest filing, from $37.2 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $66.0 million in Q4 2021 and bottomed at $7.6 million in Q4 2018.
• The 4-year median for Long-Term Deferred Tax is $27.6 million (2019), against an average of $32.2 million.
• Across the five-year window, Long-Term Deferred Tax jumped 135.53% in 2019 and jumped 77.42% in 2021, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $7.6 million in 2018, then jumped by 135.53% to $17.9 million in 2019, then surged by 107.82% to $37.2 million in 2020, then soared by 77.42% to $66.0 million in 2021.
• Per Business Quant, the three latest STOK Long-Term Deferred Tax figures stand at $66.0 million (Q4 2021), $37.2 million (Q4 2020), and $17.9 million (Q4 2019).